Achilles Therapeutics plc (ACHL)

0,7744 -0,0151 (-1,91%) Börsenschluss: 04:00PM EDT

Achilles Therapeutics plc

245 Hammersmith Road
London W6 8PW
United Kingdom
44 20 8154 4600
https://www.achillestx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 204

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Iraj Ali Ph.D.	CEO & Director	1,7M	N/A	1975
Dr. Karl Stuart Peggs M.D.	Founder & Chief Medical Officer	N/A	N/A	1967
Dr. Sergio A. Quezada Ph.D.	Founder & Chief Scientific Officer	N/A	N/A	1975
Mr. Robert Coutts	Chief Financial Officer	N/A	N/A	1984
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.	Founder	N/A	N/A	1963
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.	Founder	N/A	N/A	1973
Mr. Lee M. Stern	Vice President of Investor Relations & External Communications	N/A	N/A	N/A
Mr. Daniel Carey Cazel Hood	General Counsel & Company Secretary	N/A	N/A	N/A
Julia Wilson	Head of Communications	N/A	N/A	N/A
Mr. Tariq Ahmed	Executive Vice President of People	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Corporate Governance

Achilles Therapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.